Nordic Nanovector ASA News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

30.01.19	Nordic Nanovector ASA - Registration of Share Capital Increase in the Norwegian Register of Business Enterprises (PR Newswire)
28.01.19	Nordic Nanovector ASA - Notice of Extraordinary General Meeting (PR Newswire)
28.01.19	Nordic Nanovector ASA - Notice of Extraordinary General Meeting (PR Newswire)
25.01.19	Nordic Nanovector - Private Placement Successfully Completed (PR Newswire)
25.01.19	Nordic Nanovector - Private Placement Successfully Completed (PR Newswire)
24.01.19	Nordic Nanovector Launches a Private Placement of New Shares (PR Newswire)
24.01.19	Nordic Nanovector ASA (OSE: NANO) Nomination Committee Proposes New Chairman (PR Newswire)
24.01.19	Nordic Nanovector ASA (OSE: NANO) Nomination Committee Proposes New Chairman (PR Newswire)
02.01.19	Nordic Nanovector Appoints Mark Wright as Head of Manufacturing (PR Newswire)
02.01.19	Nordic Nanovector Appoints Mark Wright as Head of Manufacturing (PR Newswire)
04.12.18	Nordic Nanovector: Additional Preclinical Studies With CD37-targeting Radioimmunotherapies for B-cell Malignancies Presented at ASH (PR Newswire)
04.12.18	Nordic Nanovector: Additional Preclinical Studies With CD37-targeting Radioimmunotherapies for B-cell Malignancies Presented at ASH (PR Newswire)
03.12.18	Nordic Nanovector: Single Administration Betalutin® is Effective and Well-tolerated in R/R iNHL Patients: 6 Month Follow-up Data Presented at ASH (PR Newswire)
03.12.18	Nordic Nanovector: Single Administration Betalutin® is Effective and Well-tolerated in R/R iNHL Patients: 6 Month Follow-up Data Presented at ASH (PR Newswire)
27.11.18	Nordic Nanovector ASA: Increased Share Capital Following Exercise of Employee Share Options (PR Newswire)
27.11.18	Nordic Nanovector ASA: Increased Share Capital Following Exercise of Employee Share Options (PR Newswire)
16.11.18	Nordic Nanovector ASA: Increased Share Capital Following Exercise of Employee Share Options (PR Newswire)
16.11.18	Nordic Nanovector ASA: Increased Share Capital Following Exercise of Employee Share Options (PR Newswire)
06.11.18	Nordic Nanovector ASA: Results for the Third Quarter 2018 (PR Newswire)
06.11.18	Nordic Nanovector ASA: Results for the Third Quarter 2018 (PR Newswire)
02.11.18	Nordic Nanovector ASA: Invitation to Third Quarter 2018 Results Presentation and Webcast (PR Newswire)
02.11.18	Nordic Nanovector ASA: Invitation to Third Quarter 2018 Results Presentation and Webcast (PR Newswire)
02.11.18	Nordic Nanovector Announces First Patient Dosed in Archer-1 Trial of Betalutin® Plus Rituximab in Follicular Lymphoma (PR Newswire)
02.11.18	Nordic Nanovector Announces First Patient Dosed in Archer-1 Trial of Betalutin® Plus Rituximab in Follicular Lymphoma (PR Newswire)
01.11.18	Nordic Nanovector: Promising Results from Preclinical Studies with a Novel CD37-targeted Alpha Therapy for B-cell Tumours to be Presented at ASH (PR Newswire)
01.11.18	Nordic Nanovector Highlights Promising Clinical Results from Phase 1/2 Trial of Betalutin® in Relapsed/Refractory Indolent non-Hodgkin's Lymphoma (PR Newswire)
01.11.18	Nordic Nanovector Highlights Promising Clinical Results from Phase 1/2 Trial of Betalutin® in Relapsed/Refractory Indolent non-Hodgkin's Lymphoma (PR Newswire)
26.10.18	Nordic Nanovector Announces Opening of First US Site for PARADIGME Trial of Betalutin® in Third-line Follicular Lymphoma (PR Newswire)
26.10.18	Nordic Nanovector Announces Opening of First US Site for PARADIGME Trial of Betalutin® in Third-line Follicular Lymphoma (PR Newswire)
25.10.18	Nordic Nanovector's Betalutin® Receives Promising Innovative Medicine (PIM) Designation in the UK for the Treatment of Follicular Lymphoma (PR Newswire)
25.10.18	Nordic Nanovector's Betalutin® Receives Promising Innovative Medicine (PIM) Designation in the UK for the Treatment of Follicular Lymphoma (PR Newswire)
17.10.18	Nordic Nanovector ASA: Change of Date for Q3 2018 Results Presentation and Webcast (PR Newswire)
17.10.18	Nordic Nanovector - Financial Calendar (PR Newswire)
17.10.18	Nordic Nanovector - Financial Calendar (PR Newswire)
17.10.18	Nordic Nanovector ASA: Change of Date for Q3 2018 Results Presentation and Webcast (PR Newswire)
12.10.18	Nordic Nanovector Presentations at the Annual Congress of the European Association of Nuclear Medicine (EANM) (PR Newswire)
12.10.18	Nordic Nanovector Presentations at the Annual Congress of the European Association of Nuclear Medicine (EANM) (PR Newswire)
25.09.18	Nordic Nanovector ASA: Increased Share Capital Following Exercise of Employee Share Options (PR Newswire)
25.09.18	Nordic Nanovector ASA: Increased Share Capital Following Exercise of Employee Share Options (PR Newswire)
22.08.18	Nordic Nanovector ASA: Results for the Second Quarter and First Half 2018 (PR Newswire)
22.08.18	Nordic Nanovector ASA: Results for the Second Quarter and First Half 2018 (PR Newswire)
08.08.18	Nordic Nanovector ASA: Invitation to Second Quarter and First Half 2018 Results Presentation and Webcast (PR Newswire)
05.07.18	Nordic Nanovector ASA: Share Capital Increase Registered (PR Newswire)
05.07.18	Nordic Nanovector ASA: Share Capital Increase Registered (PR Newswire)
03.07.18	Nordic Nanovector ASA: Increase of Share Capital/Mandatory Notification of Trade and Issuance of PSUs (PR Newswire)
03.07.18	Nordic Nanovector ASA: Increase of Share Capital/Mandatory Notification of Trade and Issuance of PSUs (PR Newswire)
27.06.18	Nordic Nanovector ASA: Increased Share Capital Following Exercise of Employee Share Options (PR Newswire)
27.06.18	Nordic Nanovector ASA: Increased Share Capital Following Exercise of Employee Share Options (PR Newswire)
25.06.18	Nordic Nanovector ASA: Mandatory Notification of Trade (PR Newswire)
25.06.18	Nordic Nanovector ASA: Mandatory Notification of Trade (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Nordic Nanovector ASA

Aktien Top/Flop

Meistgelesene Nachrichten